TCGA-78-7542-01A-21R-2066-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 56
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.650
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.500
- INTERFERON_GAMMA_RESPONSE+0.480
- MITOTIC_SPINDLE+0.470
- PROTEIN_SECRETION+0.440
- MYC_TARGETS_V1+0.380
- MTORC1_SIGNALING+0.360
- PI3K_AKT_MTOR_SIGNALING+0.330
- DNA_REPAIR+0.320
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.340
- WNT_BETA_CATENIN_SIGNALING-0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- KRAS_SIGNALING_DN-0.300
- HEDGEHOG_SIGNALING-0.280
- BILE_ACID_METABOLISM-0.220
- MYOGENESIS-0.220
- UV_RESPONSE_UP-0.130
- NOTCH_SIGNALING-0.110
- ANGIOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-AAN2-01A-11R-A42T-07 | — | — | 0.886 |
| 2 | TCGA-78-7146-01A-11R-2039-07 | — | cohortA1 | 0.867 |
| 3 | TCGA-CQ-6220-01A-11R-1915-07 | — | — | 0.839 |
| 4 | TCGA-85-7710-01A-11R-2125-07 | — | cohortSQ1 | 0.834 |
| 5 | TCGA-4Z-AA81-01A-11R-A39I-07 | — | — | 0.833 |
| 6 | R427 | — | — | 0.830 |
| 7 | SRR650153 | — | — | 0.823 |
| 8 | TCGA-52-7812-01A-11R-2125-07 | — | cohortA1 | 0.816 |
| 9 | SRR934975 | — | — | 0.810 |
| 10 | TCGA-G2-A2EJ-01A-11R-A180-07 | — | — | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.650 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.470 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.440 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.330 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |